Aug 24 (Reuters) - Grand Investment International Ltd :
* LEE WAI TSANG ROSA HAS TENDERED HER RESIGNATION AS AN EXECUTIVE DIRECTOR Source text for Eikon: Further company coverage:
Aug 24 (Reuters) - Grand Investment International Ltd :
* LEE WAI TSANG ROSA HAS TENDERED HER RESIGNATION AS AN EXECUTIVE DIRECTOR Source text for Eikon: Further company coverage:
Micro shorts for men: how short is too short?With lockdown easing, will you be following Paul Mescal and Harry Styles and baring more leg than usual this summer? Sun’s out, thighs out? John Travolta in Perfect, Harry Styles at Guccifest, and Tom Selleck as Magnum PI. Composite: Rex/Shutterstock/Gucci
In honor of National Volunteer Month, Nepris, an online, cloud-based platform that virtually connects students with industry volunteers all over the U.S., is hosting the "You Give, We Give" campaign. As part of the month-long campaign, Nepris is donating free access to the platform to a school in need for one year and $7,500 to like-minded nonprofit organizations to expand career opportunities for underserved communities.
Amy Winehouse: the spiteful way she was treated still fills me with rageIt’s hard to say whether Amy’s death shocked the music industry into better protecting artists experiencing mental ill health but I’m hopeful things are changing for the better ‘The alluring sense that I was instantly cooler for listening’ ... Amy Winehouse performing at Glastonbury in 2008. Photograph: James McCauley/Rex/Shutterstock
United States Steel Corporation to Release First Quarter 2021 Financial Results on April 29, 2021.
Voya Financial, Inc. (NYSE: VOYA), announced today that Yvette Butler, 55, president, SVB Private Bank & Wealth Management, has joined the company’s board of directors. She will serve on the compensation and benefits committee; the nominating and governance committee; and the risk, investment and finance committee.
Kohl’s Corporation (NYSE: KSS) announced today the upsize and early tender results as of 5:00 p.m., New York City time, April 9, 2021 (the "Early Tender Deadline") for the previously announced cash tender offer (the "Tender Offer") for its 9.500% Notes due 2025, 4.250% Notes due 2025, 4.750% Notes due 2023 and 3.250% Notes due 2023 (collectively, the "Notes").
OMER, Israel, April 12, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced that Polyrizon Ltd. (which Medigus owns 33.24% of its share capital), a private company engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, commenced a pre-clinical trial to examine its bio-gel efficacy to protect against coronavirus infection. Polyrizon develops an innovative technology, designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities. Polyrizon’s technology is comprised of a bio-gel that is applied topically, and can be formulated both for wet and dry administration. Polyrizon plans on testing a number of different formulations of its highly differentiae biological gel for protection against coronavirus, and on screening several new formulations designed to prevent coronavirus from effecting epithelial cells. The trial results will provide guidance to Polyrizon for future regulatory process, as well as refine its existing formulations, and facilitate in the determination of which formulation is the most promising. About Medigus Medigus is traded on the Nasdaq Capital Market. To learn more about the company’s advanced technology, please visit www.medigus.com. Cautionary Note Regarding Forward Looking Statements This press release may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions and expectations of Medigus’ management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. For example, Medigus uses forward looking statements when describing Polyrizon’s intention on testing a several formulations of its biological gel for protection against coronavirus, Polyrizon’s purpose of screening several new formulations and the implications of the trial results on Polyrizon’s regulatory process and pathway. These forward-looking statements represent Medigus’ expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the Medigus’ activity to differ significantly from the content and implications of such statements. Other risk factors affecting Medigus and Polyrizon are discussed in detail in the Medigus’ filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and Medigus undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither Medigus nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Medigus’ securities. Nothing in this press release should be deemed to be medical or other advice of any kind Contact (for media only) Oz Adler Chief Financial Officer +972-8-6466-880 email@example.com
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has been named one of Fortune’s 100 Best Companies to Work For® in the United States. This is Horizon’s first time being included on the list.
- Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership - BEDFORD, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Tim Kelly has been promoted to Chief Operating Officer, effective immediately. Previously, Mr. Kelly held the role of Chief Technical Operations Officer and led the construction of the Company’s internal 25,000-square-foot GMP manufacturing facility, which was completed in 12 months from design to operation. As one of the first companies to scale to a 2,000-liter bioreactor with a HEK293 serum-free suspension system, Homology’s commercial scale process and platform gives the Company the ability to produce large scale volumes to support its gene therapy and editing programs, and can be further leveraged to target larger disease areas. “From the beginning, Tim was a major driver behind the strategic decision to invest in developing our process and internal manufacturing capabilities, including realizing the value of operating under the same roof as our research and process development labs,” stated Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines. “Tim’s more than 20 years of technical knowledge and business operations experience has been key to progressing our dual gene therapy and editing platform, and we look forward to his broader contributions to our organization as we continue to advance our mission to bring genetic medicines to patients.” Under his leadership, Homology has attracted and grown a highly experienced technical operations team, some of whom worked alongside Mr. Kelly in developing the first commercially approved, single-use bioreactor manufacturing system many years ago while at Shire plc. This experience, coupled with Tim’s strategic vision, enabled the rapid development and optimization of Homology’s “plug and play” platform that currently serves all programs, regardless of the modality or transgene. With 3,500 liters of total capacity, Homology is advancing its Phase 2 pheNIX gene therapy clinical trial, for which it expects to report initial data by the end of this year, and plans to initiate two other clinical programs, including its first gene editing trial. Mr. Kelly is an industry leader with a successful track record that spans senior roles at Shire plc, Sarepta Therapeutics, Inc., Biogen Idec and UCB S.A. He has been featured in many industry articles and panels and plans to participate in the upcoming 5th Annual Chardan Genetic Medicines Manufacturing Summit taking place on Tuesday, April 27 at 1:00 p.m. ET, where he will present on Homology’s manufacturing process and platform. About Homology Medicines, Inc. Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases. The Company’s intellectual property covers its family of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visit www.homologymedicines.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans and timing for the release of clinical data and for the initiation of additional clinical programs; our beliefs regarding our manufacturing capabilities; our position as a leader in the development of genetic medicines; and participation in upcoming presentations and conferences. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the capabilities of our manufacturing facility; risks relating to the regulatory approval process; our product candidates may cause serious adverse side effects; initial, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Company ContactsTheresa McNeelyChief Communications Officer and Patient Advocatetmcneely@homologymedicines.com781-301-7277 Media Contact:Marisa CitranoSenior Corporate Communications Associatemcitrano@homologymedicines.com617-335-2841
TORONTO and CHICAGO and MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731), today announced that Ken d’Entremont, CEO, and Roland Boivin, CFO, will be participating in the Bloom Burton & Co. Healthcare Investor Conference as well as the Stifel 2021 Canada Cross Sector Insight Conference in the month of April. Bloom Burton & Co. Healthcare Investor Conference Date: Tuesday, April 20, 2021Time: 11a.m. ETRegister for the virtual conference: click here The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings. Stifel 2021 Canada Cross Sector Insight Conference Medexus will also be participating in several one-on-one investor meetings on Wednesday, April 21, 2021 at the Stifel 2021 Canada Cross Sector Insight Conference. Investors should contact their Stifel representatives for more details. About Medexus Pharmaceuticals Inc. Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action. For more information, please contact: Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail: firstname.lastname@example.org Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail: email@example.com Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020E-mail: firstname.lastname@example.org Investor Relations (Canada):Tina ByersAdelaide CapitalTel: 905-330-3275E-mail: email@example.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Increasing development of protein-based therapeutics, rising focus on proteomics research use of crystallization to elucidate protein structures are key factors driving revenue growth of the marketNew York, April 12, 2021 (GLOBE NEWSWIRE) -- Market Size – USD 1.10 Billion in 2020, Market Growth – at a CAGR of 9.2%, Market Trends – Increasing use of protein crystallography in drug discovery & development The global protein crystallization & crystallography market size is expected to reach USD 2.23 Billion By 2028 at a CAGR of 9.2%, according to the latest report by Reports and Data. Rapid technological advancements in protein crystallography and increasing demand for protein therapeutics are some key factors expected to boost adoption of protein crystallization technique and this is expected to drive market revenue growth over the forecast period. Increasing use of protein crystallography in drug discovery and development to cater to unmet medical needs is also a key factor expected to boost revenue growth of the market over the forecast period. Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3966 Protein crystallization is the process of forming protein crystals that offer key insights into protein function and helps researchers understand the inner workings of a living cell. X-ray crystallography and neutron diffraction are extensively used to produce atomic level structural images of proteins and other biological macromolecules. Protein crystallization is considered a crucial tool for demonstrating chemical purity of proteins and for their purification. Protein crystallography has also widely been used for drug discovery and development processes. Increasing demand for protein therapeutics has been observed in the recent past owing to increased use in treatment of various chronic diseases such as cancer, diabetes, and multiple sclerosis, among others. High-throughput crystallography is considered to be a vital tool in drug discovery processes as it offers a quick way to tailor drug candidates to specific targets. This is expected to further boost market revenue growth over the forecast period. However, high initial costs associated with equipment used in crystallization experiments and dearth of skilled and trained professionals are expected to restrain market growth to a certain extent over the forecast period. In addition, lack of availability of standardized protocol for protein crystallization experiments are expected to hamper market growth to a significant extent over the forecast period. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/protein-crystallization-and-crystallography-market Some Key Highlights from the Report: X-ray crystallography segment is expected to register significant revenue growth over the forecast period owing to increasing use of the technique for elucidating membrane protein structure and in drug discovery and development. Consumable segment revenue is expected to expand considerably over the forecast period owing to increasing demand for reagents & kits and microplates for research and increasing application of reagents and kits in protein chemistry.Pharmaceutical company segment is expected to register considerable revenue CAGR over the forecast period owing to increasing application of protein crystallization in drug delivery procedures and rising demand for protein therapeutics.Asia Pacific is expected to account for a significant share in the global market in terms of revenue over the forecast period. Growth can be attributed to increasing awareness about protein crystallization techniques, increasing proteomics research, and increasing need for discovery and development of novel drug candidates to cater to increasing medical needs.In March 2021, Bruker Corporation announced the launch of its new plasma proteomics software and consumables for chemical cross linking of proteins to further advance proteomics research. Key companies in the global market include: Rigaku CorporationHampton ResearchJena Bioscience GmbHBruker CorporationMolecular Dimensions Ltd.Formulatrix, Inc.MiTeGen LLCBiogenuixArinax Scientific InstrumentationHiMedia Laboratories Order Now: https://www.reportsanddata.com/checkout-form/3966 For the purpose of this report, Reports and Data has segmented the global protein crystallization & crystallography market based on technology, product & service, end-use, and region: Technology Outlook (Revenue, USD Billion; 2018-2028) X-ray Crystallography Nuclear Magnetic Resonance (NMR) Product and Service Outlook (Revenue, USD Billion; 2018-2028) Consumables Microplates 96 well-plates48-well plates24-well plates Crystal Mounts and LoopsReagents Kits/ScreensOther Consumables Instruments Liquid Handling Instruments AutomatedManual Crystal Imaging Instruments Software & Services End-Use Outlook (Revenue, USD Billion; 2018-2028) Pharmaceutical CompaniesBiotechnology CompaniesGovernment InstitutesAcademic Institutes Regional Outlook (Revenue, USD Billion; 2018-2028) North America U.S.CanadaMexico Europe GermanyU.K.ItalyFranceBENELUXRest of Europe Asia Pacific ChinaIndiaJapanSouth KoreaRest of APAC Latin America BrazilRest of LATAM Middle East & Africa Saudi ArabiaU.A.E.South Africa Rest of MEA Browse similar research reports: Spatial Genomics & Transcriptomics Market Size, Share & Analysis, By Technique (Spatial Transcriptomics, Spatial Genomics), By Product (Instruments, Consumables, Software), By Application (Drug Discovery, Translational Research), By End-user (Academic & Research Institutes, CROs, Pharmaceutical, And Biotech Companies), And By Region, Forecast To 2028 Microbial Culture Market Size, Share & Analysis, By Product Type (Media, Reagents, Sera), By Application (Food & Water Testing, Bioenergy & Agricultural Research), And By Region, Forecast To 2028 About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John W Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: firstname.lastname@example.org Read Full Press Release: https://www.reportsanddata.com/press-release/global-protein-crystallization-and-crystallography-market
Boosted.ai, the leading distributed machine learning platform for global investment professionals, today announced it will provide its machine learning platform, Boosted Insights, to China Asset Management Co., Ltd. (ChinaAMC), one of the largest fund management firms in China ($245.5B AUM as of December 31, 2020).
Popular, Inc. ("Popular" or the "Corporation") (NASDAQ: BPOP) announced today the following capital actions:
EJF Capital LLC ("EJF"), a global alternative asset management firm, today announced the launch of its second real estate Qualified Opportunity Zone Fund, EJF OpZone Fund II LP (the "Fund").
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced the company won four 2021 Comparably Awards from the employee sentiment career site that generates millions of workplace ratings across 60,000 U.S. companies. The latest honors include:
GUANGZHOU, China, April 12, 2021 (GLOBE NEWSWIRE) -- LIZHI INC. (“LIZHI” or the “Company”) (NASDAQ: LIZI), a leading online UGC audio community and interactive audio entertainment platform in China, announced that it successfully held its 2021 LIZHI Voice Festival (“Voice Festival” or “Festival”) on April 10th. The Festival is a voice carnival event created by the Company, and has been successfully held for two sessions since 2018. The 2021 Festival was held online and gathered various celebrities, top content creators of the LIZHI App and their fans. It leveraged an immersive online concert and innovative voice interaction experiences to cement the brand of “Voice Festival” while simultaneously becoming closer to the new-generation user group. This year’s Festival invited multiple celebrities and artists to interact with fans, including Yan Yu, a member of popular idol group THE9, Xikan Li, the leader of idol group S.K.Y., singer Amber J. Liu, famous host Da Zuo and experienced voice actor and director Ketsu. During the Festival, these celebrities and artists also helped award the content creators who won in the 2020 annual competition of the LIZHI App. Among the selected content creators, Dakai Talk won “the best individual podcast award of 2020” and Beijing Bro. Talk Show Radio won “the honorary podcast award of 2020”. In addition, after the Festival, LIZHI will coordinate with some of the celebrities and artists who joined the Festival to unveil customized podcasts in which they will share their daily lives with fans. Mr. Jinnan (Marco) Lai, Founder and Chief Executive Officer of LIZHI, commented, “We are very pleased to have successfully hosted the LIZHI Voice Festival. As a highly active online audio community, LIZHI App has been dedicated to allowing everyone to showcase vocal talent, creating a unique community ecosystem. Our distinctive format of an immersive online interactive concert enabled our young user base to communicate and interact with their favorite idols and artists in the livestreaming room, and get closer to them through diversified interactive functions. In addition, awarding the top content creators of 2020 is another essential part of the Festival, as content creators are the cornerstone of LIZHI’s immersive UGC content library. Through this award ceremony, we aimed to help the content creators amplify their influence to gain attention from a larger audience group while further generating more income. In the future, we will remain focused on optimizing and upgrading the social interaction functions in our community while cooperating with more celebrities and artists for new content offerings. We believe the effort will engage more younger generation users on our platform to obtain extensive audio content offerings and interact with each other.” About LIZHI INC. LIZHI INC. has built an audio ecosystem with a global presence consisting of audio-based social networks, podcast content portfolios and audio communities. The Company aims to bring people closer together through voices by its product portfolios. LIZHI’s audio-based social networking products offering, including Tiya App, caters to users’ evolving interest in social interactions in real time online and enables users to connect with friends having similar interests, entertain, chat online, and share their daily lives through voices. LIZHI also offers a vertical podcast platform, LIZHI Podcast, that provides users with curated content drawn from its extensive content library built over the years, as well as new podcasts provided by selected content creators. Since the launch of LIZHI App in 2013, the Company’s flagship platform, LIZHI has cultivated a vibrant and growing online UGC audio community and interactive audio entertainment platform where users are encouraged to create, share, discover and enjoy audio, and experience immersive and diversified entertainment features through audio. LIZHI envisions a global audio ecosystem – a place where everyone can be connected through voices and across cultures. LIZHI INC. has been listed on Nasdaq since January 2020. For more information, please visit: http://ir.lizhi.fm. Safe Harbor Statement This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the Securities Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law. For investor and media inquiries, please contact: In China:LIZHI INC.IR DepartmentTel: +86 (20) 3866-4265E-mail: email@example.com The Piacente Group, Inc.Jenny CaiTel: +86 (10) 6508-0677E-mail: Lizhi@tpg-ir.com In the United States:The Piacente Group, Inc.Brandi PiacenteTel: +1-212-481-2050E-mail: Lizhi@tpg-ir.com
HOUSTON, April 12, 2021 (GLOBE NEWSWIRE) -- TC Energy Corporation (TSE, NYSE: TRP) (TC Energy or the Company) announced today that it is seeking, through the issuance of a Request for Information (RFI), to identify potential contract and/or investment opportunities in wind energy projects that could generate up to 2,500,000 megawatt hours per year or 620 megawatts of zero-carbon energy to meet the electricity needs for a portion of its pipeline assets along its U.S. corridor. The RFI, issued by Marathon Capital (Marathon) on behalf of the Company, is non-binding and does not commit TC Energy to any further action if the indicative terms received pursuant to the RFI are not satisfactory. Selection process and timingThe RFI is open from April 12 to May 10, 2021 and will be issued to approximately 100 renewable development companies to identify suitable wind energy projects across the Southwest Power Pool (SPP), Midwest Independent System Operator (MISO) and Electric Reliability Council of Texas (ERCOT) power regions. RFI responses received will be reviewed and a shortlist of parties will be invited to move to a request for proposal (RFP) process during which TC Energy will conduct detailed due diligence of the projects. All participants must direct their inquiries through Marathon. Quote Corey Hessen, TC Energy Senior Vice-President and President, Power and Storage, said the RFI is an important step in advancing the Company’s plans to leverage its Power business as a platform for future growth and diversification, building on 20 years of expertise and total assets of $100 billion. TC Energy currently owns or has interests in seven power generation facilities in four Canadian geographies with combined capacity of approximately 4,200 megawatts — enough to power more than four million homes. “We are exploring opportunities to electrify and use renewable energy to power certain TC Energy proprietary energy loads,” said Hessen, adding that the Company is also actively evaluating options to invest directly in renewable projects where possible. “Ultimately, our goal is to leverage our existing asset base to add more renewable generation into our portfolio and the broader market, resulting in a net reduction of emissions across our North American footprint,” Hessen added. About TC EnergyWe are a vital part of everyday life — delivering the energy millions of people rely on to power their lives in a sustainable way. Thanks to a safe, reliable network of natural gas and crude oil pipelines, along with power generation and storage facilities, wherever life happens — we’re there. Guided by our core values of safety, responsibility, collaboration and integrity, our 7,500 people make a positive difference in the communities where we operate across Canada, the United States and Mexico. TC Energy’s common shares trade on the Toronto (TSX) and New York (NYSE) stock exchanges under the symbol TRP. Media Inquiries:Jennifer Link403-920-7859 or 800-608-7859 Investor & Analyst Inquiries:David Moneta / Hunter Mau403-920-7911 or 800-361-6522 Marathon CapitalJoan Hutchinsonjhutchinson@marathoncapital.com503-953-3324 PDF available: http://ml.globenewswire.com/Resource/Download/07f61431-c4f0-49d5-97bc-e442484dd8ea
TORONTO, April 12, 2021 (GLOBE NEWSWIRE) -- April 12, 2021 – VITALHUB CORP. (TSXV: VHI) (the “Company” or “VitalHub”), is pleased to announce today it has entered into an agreement (the “Agreement”) with Jayex Healthcare Limited (ASX: JHL) (“Jayex”), a leading UK and Australian e-health provider of integrated SaaS healthcare services delivery platforms, to purchase the assets (the “Acquisition”) of Jayex’s on-premise hospital queue management business segment (“Jayex System”). Total consideration to be paid by VitalHub is expected to be £1.3M (the “Purchase Price”). Jayex will receive the Purchase Price as (i) £1.04M in cash and (ii) £0.26M in VitalHub common shares (the “Shares”). The Shares are to be issued at CAD$2.915 per Share, and will result in 150,078 Shares being issued. In addition, for 24 months after closing of the Acquisition, Jayex may receive an earn-out based on earned revenues of the Jayex System, capped at a total of £1M. The Company currently has 36,146,564 Common Shares issued and outstanding. Upon delivery of the Shares, the Company will have a total 36,296,642 issued and outstanding common shares. VitalHub anticipates that the Acquisition will close in approximately three weeks and is subject to customary closing conditions including ongoing due diligence of the Jayex System by VitalHub. Dan Matlow, VitalHub CEO, commented that “we are excited to welcome Jayex customers into VitalHub’s subsidiary “Intouch with Health”. With this acquisition VitalHub will now significantly increases its number of customers using at least one module of our patient journey solutions within the UK and Australia. This deal affords VitalHub the opportunity to introduce the Jayex customer base to our entire product portfolio”. ABOUT THE JAYEX SYSTEM The Jayex System is an on-premise hospital queue management system, much like VitalHub’s “Intouch with Health” product offering, and is installed at almost 60 customer sites in the UK and Australia, representing recurring annual software revenue of approximately £420K. ABOUT VITALHUB VitalHub provides technology to Health and Human Services providers designed to simplify the user experience & optimize outcomes. VitalHub customer organisations include Hospitals, Regional Health Authorities and organizations providing services relating to Mental Health, Long Term Care, Home Health, Community, and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps. The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol “VHI”. CONTACT INFORMATION VitalHubDan MatlowChief Executive Officer, Director(416) firstname.lastname@example.org CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer's business, capital, or operations that is prospective in nature, and includes future-oriented financial information about the issuer's prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the terms of the Acquisition. VitalHub made certain material assumptions, including but not limited to: Jayex annual revenues, prevailing market conditions; general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the ability of VitalHub and Jayex to execute and achieve its business objectives, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to: adverse market conditions; the inability of VitalHub and Jayex to complete the Acquisition on the terms disclosed in this news release, or at all; reliance on key and qualified personnel; and regulatory and other risks associated with the medical and technology industries in general. The foregoing list of material risk factors and assumptions is not exhaustive. VitalHub assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.
SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., April 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in a Phase 1 trial evaluating ALLO-715, Allogene’s investigational anti-B-cell maturation antigen (BCMA) AlloCAR T therapy, in combination with nirogacestat, SpringWorks’ investigational gamma secretase inhibitor (GSI), in patients with relapsed or refractory multiple myeloma. “We are pleased to have initiated this portion of the UNIVERSAL trial and look forward to investigating ALLO-715 in combination with nirogacestat as part of our comprehensive anti-BCMA strategy aimed at bringing an off-the-shelf cell therapy to patients with relapsed or refractory multiple myeloma,” said David Chang, M.D., Ph.D., President, CEO and Co-Founder of Allogene Therapeutics. Gamma secretase inhibition prevents the cleavage and shedding of BCMA from the surface of multiple myeloma cells. In preclinical models, nirogacestat has been shown to increase the cell surface density of BCMA and reduce levels of soluble BCMA, which may enhance the activity of BCMA-targeted therapies.1 In addition, emerging clinical data suggest that a GSI may increase antitumor efficacy of BCMA-targeted autologous CAR T therapy in patients with relapsed and refractory multiple myeloma.2,3 “Multiple myeloma is incurable for the overwhelming majority of patients diagnosed with this cancer and those who have relapsed or are refractory to current treatments have very limited therapeutic options available to them,” said Saqib Islam, Chief Executive Officer of SpringWorks Therapeutics. “SpringWorks is advancing nirogacestat as a cornerstone of BCMA combination therapy across modalities, with the goal of potentiating BCMA therapies to provide better outcomes for patients. This study represents the first clinical trial combining nirogacestat with a CAR T therapy and we are delighted that the milestone of dosing the first patient has been achieved.” The Phase 1 trial (NCT04093596), which is part of the ongoing UNIVERSAL trial being conducted by Allogene, is an open-label study evaluating the safety, tolerability and preliminary efficacy of ALLO-715 in combination with nirogacestat in patients with relapsed or refractory multiple myeloma. The trial is being advanced pursuant to a clinical trial collaboration agreement between Allogene and SpringWorks. Under the terms of the agreement, Allogene is sponsoring and conducting the Phase 1 study. Allogene and SpringWorks have formed a joint development committee to oversee this portion of the clinical study. About ALLO-715ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies. Multiple myeloma originates in the bone marrow and it is characterized by abnormalities in plasma cells that reproduce uncontrollably in the bone marrow and other disease sites.4 Multiple myeloma is incurable for most patients, as relapses occur despite most treatments available.5 Initial results from the Phase 1 UNIVERSAL study of ALLO-715 in relapsed/refractory multiple myeloma were presented at an oral session of the American Society of Hematology (ASH) annual meeting in December 2020. This study also uses ALLO-647, Allogene's anti-CD52 monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen. ALLO-715 utilizes the TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the BCMA target. Allogene holds the global development and commercial rights for this investigational candidate. About NirogacestatNirogacestat is an investigational, oral, selective, small molecule gamma secretase inhibitor in Phase 3 clinical development for desmoid tumors, which are rare and often debilitating and disfiguring soft-tissue tumors. Gamma secretase cleaves multiple transmembrane protein complexes, including Notch, which is believed to play a role in activating pathways that contribute to desmoid tumor growth. In addition, gamma secretase has been shown to directly cleave membrane-bound BCMA, resulting in the release of the BCMA extracellular domain, or ECD, from the cell surface. By inhibiting gamma secretase, membrane-bound BCMA can be preserved, increasing target density while reducing levels of soluble BCMA ECD, which may serve as decoy receptors for BCMA-directed therapies. Nirogacestat’s ability to enhance the activity of BCMA-directed therapies has been observed in preclinical models of multiple myeloma. SpringWorks is evaluating nirogacestat as a BCMA potentiator and has five collaborations with industry-leading BCMA developers to evaluate nirogacestat in combinations across modalities, including with an antibody-drug conjugate, two CAR T cell therapies and two bispecific antibodies. In addition, SpringWorks and Fred Hutchinson Cancer Research Center have entered into a sponsored research agreement to further characterize the ability of nirogacestat to modulate BCMA and potentiate BCMA directed therapies using a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch. Nirogacestat has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of desmoid tumors and from the European Commission for the treatment of soft tissue sarcoma. The FDA also granted Fast Track and Breakthrough Therapy Designations for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn. About SpringWorks TherapeuticsSpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, please visit www.springworkstx.com, and follow @SpringWorksTx on Twitter and LinkedIn. Allogene Forward-Looking StatementsThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to progress the UNIVERSAL trial and combination of ALLO-715 with nirogacestat; the ability of ALLO-715 in combination with nirogacestat to provide better outcomes for patients; the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-K for the year ended December 31, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ is a trademark of Allogene Therapeutics, Inc. SpringWorks Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results, and other future conditions. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “would,” “should” and “could,” and similar expressions or words, identify forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks relating to: (i) the success and timing of our product development activities, including the initiation and completion of SpringWorks’ clinical trials, (ii) the fact that interim data from a clinical study may not be predictive of the final results of such study or the results of other ongoing or future studies, (iii) the success and timing of our collaboration partners’ ongoing and planned clinical trials, (iv) our ability to obtain and maintain regulatory approval of any of our product candidates, (v) our plans to research, discover and develop additional product candidates, (vi) our ability to enter into collaborations for the development of new product candidates, (vii) our ability to establish manufacturing capabilities, and our and our collaboration partners’ abilities to manufacture our product candidates and scale production, (viii) our ability to meet any specific milestones set forth herein, and (ix) uncertainties and assumptions regarding the impact of the COVID-19 pandemic on SpringWorks’ business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. For further information regarding the risks, uncertainties and other factors that may cause differences between SpringWorks’ expectations and actual results, you should review the “Risk Factors” in Item 1A of Part I of SpringWorks’ Annual Report on Form 10-K for the year ended December 31, 2020, as well as discussions of potential risks, uncertainties and other important factors in SpringWorks’ subsequent filings. Allogene Media/Investor Contact:Christine CassianoChief Communications Officer(714) 552-0326Christine.Cassiano@allogene.com SpringWorks Media/Investor Contact:Kim DiamondVice President, Communications and Investor Relations203-561-1646 email@example.com References: 1 Eastman et al., Abstract #4401 “Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with Nirogacestat (PF-03084014, gamma-secretase inhibitor) in BCMA-Expressing Cancer Cell Lines”, ASH 2019. 2 Cowan et al., Abstract #204 “Efficacy and Safety of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma”, ASH 2019. 3 Blood. 2019 Nov 7;134(19):1585-1597. doi: 10.1182/blood.2019000050 4 Multiple myeloma - Genetics Home Reference - NIH. Retrieved from https://ghr.nlm.nih.gov/condition/multiple-myeloma# 5 Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396-406